No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
MannKind Corporation (MNKD): Among the Best Cancer Stocks to Invest in for Long-Term Gain
MannKind (MNKD) Receives a Buy From RBC Capital
Wells Fargo Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $9
MannKind's Promising Growth Potential: Buy Rating Backed by Strong Financials and Strategic Advancements
MannKind's Q1 Adjusted Earnings, Revenue Increase
MannKind | 10-Q: Q1 2025 Earnings Report